Compare OMEX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | CNTB |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.8M | 128.6M |
| IPO Year | N/A | 2021 |
| Metric | OMEX | CNTB |
|---|---|---|
| Price | $2.24 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 848.5K | 159.8K |
| Earning Date | 11-12-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $467,122.00 | ★ $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.51 |
| 52 Week High | $4.43 | $3.28 |
| Indicator | OMEX | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 58.83 |
| Support Level | $2.17 | $2.11 |
| Resistance Level | $2.36 | $2.65 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 18.37 | 77.43 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.